Event
Event
Neuroscience
Event
The inspiring potential of gene therapy in neurology
September 7, 2022 · BioVoxV-Bio Ventures portfolio company Biodol Therapeutics nominates its first preclinical candidate as a next-generation therapy for neuropathic pain
Ghent, Belgium, 31 August 2022 – V-Bio Ventures portfolio company Biodol Therapeutics, a French biotech company developing next-generation neuropathic pain […] August 31, 2022 · V-Bio Ventures
Augustine Therapeutics: time to reverse nerve damage in patients undergoing chemotherapy or with Charcot-Marie-Tooth disease
Augustine Therapeutics is a VIB and KU Leuven spin-off developing innovative therapies for peripheral and central nervous system disorders. The […] August 17, 2022 · V-Bio VenturesAugustine Therapeutics appoints Gerhard Koenig as Chairman of the Board, forms Clinical Advisory Board, and broadens therapeutic indications
Leuven, Belgium, 10 May 2022 – Augustine Therapeutics, a biotech company developing novel therapies for neuromuscular and neurodegenerative disorders, appoints […] May 10, 2022 · Turnstone Communications
Abscint labels antibodies with radioactive material to spot harmful cells
Abscint is one of several Belgian biotech companies using single-domain antibodies. But unlike the others, Abscint is using these antibodies […] March 16, 2022 · BioVoxV-Bio Ventures’ Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio
Ghent, Belgium, 1 March 2022 – V-Bio Ventures today announced the completion of the acquisition of its portfolio company Syndesi […] March 1, 2022 · V-Bio Ventures
Confo-dently into the future!
Confo Therapeutics is a rising star in Belgium, featured on several local and international lists of up-and-coming biotechs. The company, […] November 24, 2021 · V-Bio Ventures
Biogen’s controversial Alzheimer’s drug approved by the FDA – what now?
It has been three months since the much-discussed FDA approval of Biogen’s Aduhelm, a treatment for Alzheimer’s Disease. The drug […] September 22, 2021 · V-Bio VenturesNewton Biocapital invests in NeuVasQ: EUR 20 million Series A to develop unique blood-brain barrier therapy
– Newton together with public and private investment partners invests in NeuVasQ for the development of blood-brain barrier pharmaceuticals based […] June 22, 2021 · Turnstone Communications
To fund or not to fund: the psychology of investment decisions
Much has been written about the psychology of decision making and how venture capitalists choose which companies they want to […] April 28, 2021 · V-Bio Ventures
Augustine Therapeutics developing new medicines for neuromuscular diseases
Augustine Therapeutics had a lot of announcements this month: the VIB spin-off just appointed Dr. Sylvain Celanire as CEO, strengthened […] March 31, 2021 · Turnstone CommunicationsAugustine Therapeutics awarded EUR 1.2 million VLAIO research grant to develop new medicines for neuromuscular diseases
Leuven, Belgium, 23 March 2021 – Augustine Therapeutics, a biotech spin-out company from VIB that focuses on the development of […] March 23, 2021 · Turnstone CommunicationsAugustine Therapeutics strengthens Board of Directors and sets up Scientific Advisory Board
Leuven, Belgium, 19th March 2021 – Augustine Therapeutics, a biotech company focused on the development of innovative medicines for rare […] March 19, 2021 · Turnstone CommunicationsAugustine Therapeutics appoints Sylvain Celanire as CEO to accelerate development of innovative medicines for rare neuromuscular diseases
Leuven, Belgium, 18th March 2021 – Augustine Therapeutics, a biotech company focused on the development of innovative medicines for rare […] March 18, 2021 · Turnstone Communications
Prestigious prize for Belgian breakthrough in brain research
Prof. Dr. Pierre Vanderhaeghen from VIB-KU Leuven has been awarded the Generet Prize for Rare Diseases for his research on […] January 27, 2021 · BioVox
Decades-old discoveries cause paradigm shifts in modern medicine
Complete paradigm shifts in medicine are rare, but there have nevertheless been several major examples in the past hundred years. […] December 16, 2020 · V-Bio Ventures
A novel approach to neurology could bring relief to people in pain
In August 2020, V-Bio Ventures announced their investment in Biodol Therapeutics, a French start-up looking to make a difference to […] August 31, 2020 · V-Bio VenturesBiodol Therapeutics receives EUR 4.5 million to progress its novel pain medication in a Series A led by V-Bio Ventures
V-Bio Ventures, a leading Belgian life sciences VC, invests in Biodol Therapeutics, a French biotech specialized in next-generation chronic pain […] August 31, 2020 · V-Bio Ventures
Magic mushrooms in modern medicine
This article was authored by Katja Rosenkranz from V-Bio Ventures. More than 75 years after the initial discovery of lysergic acid […] November 26, 2019 · V-Bio Ventures
Orphan CNS diseases receive attention with new Minoryx site in Belgium
The Spanish start-up Minoryx Therapeutics recently opened a subsidiary in Belgium to further their research on treatments for rare and […] March 4, 2019 · BioVox
Microbiome linked to depression in a groundbreaking Benelux study
The microbiome had been at the forefront of a lot of research and news in the past few years. Now, […] February 19, 2019 · BioVox
Rewind Therapeutics secures funding for Multiple Sclerosis research
Rewind Therapeutics, a privately held Belgian biotech company, completed a € 15.2 million Series A financing to develop novel re-myelinating […] January 11, 2018 · Turnstone Communications
Liesbeth Aerts in Sydney - Belgian scientist living abroad
Until August 2017, Liesbeth Aerts lived in Sydney, where she worked as a dementia researcher at the University of New […] October 9, 2017 · BioVox
Sylvie Janssen in Manhattan - Belgian scientist living abroad
Sylvie Janssens lives in Manhattan, New York, where she relocated after earning her PhD in biotechnology at Ghent University. She […] June 8, 2017 · BioVox
Reversed Brexit: £250 million for Bart De Strooper's dementia research
The UK has pledged a budget of £250 million to the creation of the UK Dementia Research Institute (DRI). The […] April 17, 2017 · BioVox
Stop eye-balling MRI scans
Up to 1 billion people in the world suffer from neurological disorders. Currently, many brain scans are still evaluated by visual inspection. Quantification of different biomarkers in these brain scans can improve diagnosis, patient monitoring and, eventually, patient outcome. The Leuven-based company Icometrix provides software to bring quantification of brain scans into clinical trials and clinical practice. We should stop eye-balling images of brain scans and step into the world of quantitative analysis.
April 17, 2017 · Janssen Pharmaceutica
Partnering for a better mental health
To address the challenges of drug development, solid strategic partnerships are needed. On the Janssen partner day, the company showcased an ongoing partnership with the University of Antwerp in mental health and how this partnership leads to better outcomes.
March 14, 2017 · Janssen Pharmaceutica
Alzheimer's, ALS or a brain injury: ADx neurosciences knows how to tackle it
ADx NeuroSciences might be described best as the Intel of biomarker assays for neuro-degenerative disease. They don’t create complete kits, […] February 13, 2017 · Turnstone Communications
Music or neuroscience? Balthazar’s violinist chose music (at least for now)
For Patricia Vanneste, violinist with the popular rock group Balthazar, it wasn’t a choice she made lightly. Patricia has played the violin since she was five. [...] December 6, 2016 · BioVoxThe choroid plexus: where inflammation meets neurology
We write about change — about impact and consequences, about discoveries and the people behind them. This time, we introduce […] November 14, 2016 · Turnstone Communications
ADHD, a disorder cured by play
In 2013, a new BioWin project, NeuroAtt, was launched to arrive at a reliable diagnosis for ADHD (Attention Deficit Hyperactivity Disorder) and to find the least [...] October 14, 2016 · Turnstone Communications
ALS: A fierce diagnosis
Do you remember the Ice Bucket Challenge? Back in 2014, it was used to create awareness and collect donations for […] May 17, 2016 · BioVox
Peter Verwilst in Seoul – Belgian scientist living abroad
For two and a half years now, Peter Verwilst has been working and living in one of the largest, most […] March 10, 2016 · BioVox
Ending Alzheimer's before it starts
Sebastiaan Engelborghs is a neurologist specialized in neurodegenerative brain diseases and believes in the potential of early diagnosis for Alzheimer’s […] November 23, 2015 · Turnstone Communications
Birger Dieriks in Auckland - Belgian scientist living abroad
Birger Dieriks lives in Auckland, New Zealand. He studied Bioengineering at Ghent University. After finishing his studies he started a […] October 6, 2015 · BioVoxTargeting the shape of protein aggregates to treat Parkinson’s
Parkinson’s disease (PD) is the second most common neurodegenerative disorder in the world. Similar to Multiple System Atrophy (MSA) and […] September 7, 2015 · Turnstone Communications
MS slowly but surely unravels its secrets
Piet Stinissen is Professor and Dean at the Faculty of Medicine and Life Sciences at the University of Hasselt, where […] June 1, 2015 · Turnstone Communications